TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05171452

Intervention type: BIOLOGICAL
Intervention: Urine and stoll samples
Description: Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)

Intervention type: BIOLOGICAL
Intervention: Urine and stoll samples
Description: Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
Study: NCT00412373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: (3-12mg/day in 3 mg/day increments for 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: (3-12mg/day in 3 mg/day increments for 6 weeks)
Study: NCT02826720

Intervention type: OTHER
Intervention: No intervention was applied
Description: No intervention was applied

Intervention type: OTHER
Intervention: No intervention was applied
Description: No intervention was applied

Intervention type: OTHER
Intervention: No intervention was applied
Description: No intervention was applied

Intervention type: OTHER
Intervention: No intervention was applied
Description: No intervention was applied
Study: NCT01889381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow cell-based therapy & 1-drug immunosuppression.
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Study: NCT03523923

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care
Description: Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals.
Study: NCT00708253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-balloon procedure (DBE)
Description: Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-balloon procedure (SBE)
Description: Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
Study: NCT00354185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02270853

Intervention type: DEVICE
Group type: OTHER
Intervention: sleep apnea screening with ApneaLinkTM
Description: ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
Study: NCT02047344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
Study: NCT01106417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: Single Dose NeoFuse Surgical Implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MasterGraft Granules
Description: Single Dose MaterGraft Granules Surgical Implantation
Study: NCT04098055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-Made Foot Orthoses
Description: The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
Study: NCT04232969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide extended release 2mg (Bydureon)
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide extended release 2mg (Bydureon)
Description: Subcutaneous Injection
Study: NCT00833417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg
Description: Vismodegib 150 mg was provided in hard gelatin capsules.
Study: NCT02811523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin by In Vivo Lung Perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin by In Vivo Lung Perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin by In Vivo Lung Perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin by In Vivo Lung Perfusion
Study: NCT03330002

Intervention type: DEVICE
Intervention: CE-marked MANTA vascular closure device (VCD)
Description: Compile real word data on MANTA VCD.
Study: NCT02639858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PM
Description: Docetaxel PM 75mg/m2 IV infusion
Study: NCT01445548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT03951168

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine Management
Description: Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Management
Description: Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
Study: NCT00853216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride tablet 30 mg
Description: Oxycodone hydrochloride tablet 30 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxicodone™ tablet 30 mg
Description: Roxicodone™ tablet 30 mg, single dose fasting
Study: NCT03561688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthotics
Description: Insoles for shoes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard insole
Description: Sham foot orthotic
Study: NCT03702244

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cCTA with selective FFRct
Description: PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
Study: NCT04092023

Intervention type: OTHER
Group type: OTHER
Intervention: nursing education
Description: Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.

Intervention type: OTHER
Group type: OTHER
Intervention: nursing education
Description: Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
Study: NCT02314403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: A selective T-cell (lymphocyte) costimulation blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: A T-Cell Depleting Agent
Study: NCT03044600

Intervention type: OTHER
Intervention: Chart Review
Description: Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.

Intervention type: OTHER
Intervention: HRPT2 Mutation Evaluation
Description: Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
Study: NCT00713310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM
Study: NCT03081156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate / Formoterol
Description: Exercise Tolerance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycopyrrolate / Formoterol
Description: Exercise Tolerance
Study: NCT05453734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
Study: NCT00228982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT04717206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyomtric training to male badmninton players
Description: Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills.
Study: NCT02314403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: B-Cell Depleting Agent
Study: NCT06418620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral
Study: NCT00940277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Counseling
Description: Group counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Counseling
Description: Group counseling
Study: NCT00200265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet
Description: diet
Study: NCT00947648

Intervention type: OTHER
Group type: OTHER
Intervention: Raw Fruits & Vegetables
Description: Diet containing fresh fruits and vegetables in addition to cooked food.

Intervention type: OTHER
Group type: OTHER
Intervention: Cooked Foods
Description: Diet containing only cooked foods.
Study: NCT01628926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02314403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Study: NCT01628926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: Ropinirole oral administration TID up to 15.0 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPM962-placebo patch and Ropinirole-placebo tab
Study: NCT03624647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power toothbrush
Description: Experimental power toothbrush

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual toothbrush
Description: Marketed manual toothbrush
Study: NCT03135249

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
Study: NCT01459978

Intervention type: OTHER
Intervention: CUmulative SUM (CUSUM) Chart
Description: Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose
Study: NCT02300493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Asked to weigh themselves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Asked to weigh themselves
Study: NCT04096534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normotonic partial nephrectomy
Description: partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic partial nephrectomy
Description: partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
Study: NCT00312455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-eicosapentaenoic acid (EPA)
Description: 450 mg 5x/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-docosapentaenoic acid (DPA)
Description: 100mg 5x/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day
Study: NCT02314403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic Irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bone Marrow/Kidney Transplantation
Study: NCT02605525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SM101
Description: Human soluble recombinant Fcγ Receptor IIB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SM101
Description: Human soluble recombinant Fcγ Receptor IIB

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
Study: NCT04376450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental- Nonincised papillae surgical approach
Description: The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator- Entire papilla preservation technique
Description: The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
Study: NCT02674945

Intervention type: DEVICE
Intervention: Wireless Activity tracker: Fitbit
Description: Patients will wear a Fitbit flex
Study: NCT00629395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Captain's Log Computer Program
Description: 12 Computer Program
Study: NCT03437447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisticid
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisticid
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisticid
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide
Description: Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide
Description: Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide
Description: Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT03778437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subclavian vein catheterization
Description: Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: landmark techniques
Description: The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided plus needle guide techniques
Description: Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
Study: NCT03069586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment
Description: At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt